Best Fit Profiles
- adjunctive senolytic cycles
Senolytic adjunct
Quercetin
Evidence supports anti-inflammatory and blood-pressure effects in selected populations, while senolytic claims remain largely translational.
Evidence Level C
Evidence and Risk Labels
Evidence A/B/C reflects research maturity, and risk levels reflect monitoring needs. These labels support comparison, not diagnosis or treatment decisions.
See full scoring guideClinical Snapshot
- Effect Size
- Modest inflammatory and vascular biomarker support; senolytic outcomes unproven
- Safety
- Low Risk
Most strong evidence is combination-based.
Research Dosing
This reflects common ranges and protocols used in published studies, not personal medical advice.
- Typical Daily Dose
- 500-1000 mg
- Timing
- Daily or pulse-cycle depending on protocol
- Protocol Duration in Studies
- 4-12 weeks (or intermittent senolytic cycles)
Standalone data are limited; many protocols pair quercetin with other agents.